亚洲 丝袜 美腿 制服 变态_国产SUV精品一区二区五_国产在线一区二区香蕉 在线_精品亚洲国产成人av网站_国产乱子伦视频大全亚瑟影院_国产亚洲欧洲综合5388

您好，歡迎光臨上海雅吉生物商城！
工作時(shí)間：9:00-18:00
全國(guó)服務(wù)熱線(xiàn)：021-34661276

PE anti-mouse CD274 (B7-H1, PD-L1) Antibody

訂購(gòu)數(shù)量：
規(guī)格
價(jià)格庫(kù)存
訂購(gòu)熱線(xiàn)：021-34661276
我要詢(xún)價(jià)
  • 商品詳情
  • 售后服務(wù)
  • 相關(guān)文獻(xiàn)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Formulation
Phosphate buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

Application References

(PubMed link indicates BioLegend citation)
  1. Maier H, et al. 2007. J. Immunol. 178:2714.
  2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
  3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
  4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
  5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
  6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
  7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
  8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
  9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
  10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
  12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations
  1. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  2. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  3. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  4. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  5. Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed
  6. Fitzgerald B, et al. 2021. Cell Rep Methods. 1:. PubMed
  7. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  8. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  9. Shi J, et al. 2018. Immunity. 49:264. PubMed
  10. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  11. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  12. Yang M, et al. 2020. Appl Environ Microbiol. 86:00:00. PubMed
  13. Lu SX, et al. 2021. Cell. . PubMed
  14. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  15. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  16. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  17. Dichtl S, et al. 2021. Sci Adv. 7: . PubMed
  18. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  19. Vackova J, et al. 2020. Int J Mol Sci. 21:00. PubMed
  20. Jansen MAA, et al. 2019. Front Immunol. 1.852777778. PubMed
  21. Shen Y, et al. 2022. CNS Neurosci Ther. 28:46. PubMed
  22. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  23. Zhang S, et al. 2019. Mol Med Rep. 19:5377. PubMed
  24. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  25. Pauken KE, et al. 2020. Cell Reports. 31(13):107827. PubMed
  26. Guo Q, et al. 2022. Nat Commun. 13:3837. PubMed
  27. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  28. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  29. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  30. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  31. Ramos RN, et al. 2022. Clin Transl Immunology. 11:e1392. PubMed
  32. Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed
  33. Takano T, et al. 2020. Front Immunol. 11:1555. PubMed
  34. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  35. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  36. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  37. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  38. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  39. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  40. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  41. Moon S, et al. 2021. J Exp Med. 218:. PubMed
  42. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  43. van Oostrum M, et al. 2019. Nat Commun. 4.398611111. PubMed
  44. Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed
  45. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  46. Lastwika K, et al. 2016. Cancer Res . 76: 227 - 238. PubMed
  47. Ou YC, et al. 2020. ACS Nano. 1.035416667. PubMed
  48. Campesato LF, et al. 2020. Nat Commun. 3.24375. PubMed
  49. Kriegsman BA, et al. 2019. J Immunol. 203:1999. PubMed
  50. Dimitrov V, et al. 2017. J Biol Chem. 292:20657. PubMed
  51. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  52. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  53. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  54. Apte S, et al. 2011. Int J Parasitol. 41:1285. PubMed
  55. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  56. Zhao Y, et al. 2020. Immunity. 51(6):1059-1073.e9.. PubMed
  57. Pi?ón-Zárate G, et al. 2022. Molecules. 27:. PubMed
  58. Sugita S, et al. 2013. Invest Ophthalmol Vis Sci . 54:3420. PubMed
  59. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  60. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  61. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  62. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  63. Zhou Y, et al. 2022. Front Oncol. 12:825783. PubMed
  64. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  65. Nakagawa Y, et al. 2015. Immunol Lett. 167: 72-86. PubMed
  66. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  67. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  68. Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed
  69. Zheng Y, et al. 2022. Transl Res. :. PubMed
  70. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  71. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  72. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  73. Haile S, et al. 2011. J Immunol. 186:6822. PubMed
  74. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  75. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  76. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  77. Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
  78. Loptez-Albraitero A, et al. 2017. OncoImmunology. 10.1080/2162402X.2016.1267891. PubMed
  79. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
RRID
AB_2073557 (BioLegend Cat. No. 124307) AB_2073556 (BioLegend Cat. No. 124308)

Antigen Details

Structure
40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.

Gene ID
60533 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org
我要詢(xún)價(jià)
*聯(lián)系方式：
(可以是QQ、MSN、電子郵箱、電話(huà)等，您的聯(lián)系方式不會(huì)被公開(kāi))
*內(nèi)容：


微信客服
掃一掃立即咨詢(xún)


微信客服
掃一掃立即咨詢(xún)

銷(xiāo)售電話(huà)：

021-34661275

021-34661276

15301693058